CLINICAL TRIAL: A PHASE I STUDY OF THE RAF KINASE AND RECEPTOR TYROSINE KINASE I

临床试验：RAF 激酶和受体酪氨酸激酶 I 的 I 期研究

• 批准号: 8166686
• 负责人: PATRICK THOMPSON
• 金额: $ 0.11万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166686
• 关键词: BAY 54-9085; Child; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Grant; Hour; Institution; Maximum Tolerated Dose; Phase; Protein Tyrosine Kinase; Refractory; Research; Research Personnel; Resources; Rest; Solid Neoplasm; Source; Tablets; Toxic effect; United States National Institutes of Health; leukemia; raf Kinases; receptor; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Treatment with Sorafenib will result in anti-tumor activity in children with refractory solid tumors. Determine the maximum tolerated dose (MTD) and recommended phase II dose of Sorafenib (sorafenib) administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors; and to determine whether children with refractory leukemia tolerate the solid tumor MTD. Define and describe the toxicities of Sorafenib administered orally BID (approximately every 12 hours) for cycles of 28 days with no rest period between cycles. Characterize the pharmacokinetics of Sorafenib in children with refractory solid tumors or leukemias.

这个子项目是众多研究子项目之一